Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Deltex Medical interim revenues broadly flat YOY

(Sharecast News) - Medical technology business Deltex Medical Group said on Thursday that interim revenues were broadly flat year-on-year as it managed to eke out a positive underlying earnings performance in two of the first six months of the year. Deltex Medical said unaudited revenues came to £1.064m in the first half, up from £1.059m a year earlier, with a further £92,000 in orders in-hand either awaiting components or payment in advance of shipping.

Group probe unit sales rose 16% year-on-year, driven by unit growth from its international operations of 21% which came despite the company "significantly reducing" its group-wide sales team for an annualised cost saving of roughly £1.1m.

Deltex noted that in its internal models, it was anticipating a monthly EBITDA loss in H124. However, it revealed that it was actually EBITDA positive in two months and said it expects its EBITDA to continue to improve throughout H2.

Chairman Nigel Keen said: "We have made good progress during H1 in selling and creating pipeline for the new TrueVue System into the UK and EU with many of our European distribution partners purchasing the new monitors and starting to give clinical demonstrations to their customer base.

"The significant growth in our probe unit sales into the International markets shows that our plan to focus more into International markets is working, and we expect to see this continue through H2 and remain confident for the rest of the year."

As of 1050 BST, Deltex Medical shares had slumped 10.30% to 0.15p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

ECR Minerals mulls expansion into US helium market
(Sharecast News) - ECR Minerals, an exploration and development company traditionally focused on gold in Australia, announced on Friday that its board was exploring potential investments in producing helium assets in the United States.
Zenova reports solid momentum as interim loss narrows
(Sharecast News) - Fire safety and heat management technology specialist Zenova Group reported significant first-half strides in its interim results on Friday, despite a challenging financial backdrop.
Jefferies lowers target price on Life Science REIT
(Sharecast News) - Jefferies cut its price target on real estate investment trust Life Sciences REIT from 45.0p to 36.0p following a visit to the group's Cambourne Science & Technology Park.
Beowulf reports substantial first-half progress
(Sharecast News) - Mineral explorer and developer Beowulf Mining reported substantial progress across its portfolio in its interim results on Friday, particularly in advancing its key projects at Gállok in Sweden and the Graphite Anode Materials Plant (GAMP) in Finland.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.